Global Abnormal Glucose Tolerance Treatment Market, By Treatment (Diet, Exercise, Drug Therapy, Others), Diagnosis (Glycated Hemoglobin (A1C) Test,, Glucose Tolerance Test, Others), Dosage (Tablet, Capsule, Others), Route of Administration (Oral, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Abnormal Glucose Tolerance Treatment Market
Abnormal glucose tolerance treatment market is expected to gain market growth in the forecast period of 2021-2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 5.60% in the above mentioned forecast period.
Glucose tolerance is the ability to dispose of a glucose load. Glucose intolerance is the metabolic disorder in which blood glucose level increase and result in hyperglycaemia. Abnormal glucose tolerance or impaired glucose tolerance is the condition which is denoted by the glucose intolerance. Increased thirst, dry mouth, extreme tiredness, blurred vision, loss of muscle mass, drowsiness and frequent urination are the symptoms of glucose intolerance.
Rise in the prevalence of abnormal glucose tolerance due to the rising incidence of obesity, diabetes and high cholesterol are the major driving factors influencing the market growth. Growing healthcare expenditure, alcohol abuse, high consumption of smoking tobacco, development of treatment options, growing government funding and unhealthy life style are the factors that will expand the abnormal glucose tolerance treatment market.
Rise in the research and development activities and ongoing clinical trials will provide beneficial opportunities for the abnormal glucose tolerance treatment market in the forecast period of 2021-2028.
However, high cost of treatment and side effects associated with the medication are the factors that will hinder the market growth. Greater risk of cardiovascular diseases related to abnormal glucose tolerance will challenge the abnormal glucose tolerance treatment market in the forecast period mentioned above.
This abnormal glucose tolerance treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the abnormal glucose tolerance treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Abnormal Glucose Tolerance Treatment Market Scope and Market Size
The abnormal glucose tolerance treatment market is segmented on the basis of treatment, diagnosis, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of treatment, the abnormal glucose tolerance treatment market is segmented into diet, exercise, drug therapy and others. Drug therapy has been further sub-segmented into metformin, acarbose and others.
- On the basis of diagnosis, the abnormal glucose tolerance treatment market is segmented into Glycated Hemoglobin (A1C) Test, glucose tolerance test and others.
- On the basis of dosage, the abnormal glucose tolerance treatment market is segmented into tablet, capsule and others.
- On the basis of route of administration, the abnormal glucose tolerance treatment market is segmented into oral, and others.
- On the basis of end-users, the abnormal glucose tolerance treatment market is segmented into clinic, hospital and others.
The abnormal glucose tolerance treatment market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Abnormal Glucose Tolerance Treatment Market Country Level Analysis
Abnormal glucose tolerance treatment market is analyzed and market size information is provided by the country, treatment, diagnosis, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the abnormal glucose tolerance treatment market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the abnormal glucose tolerance treatment market due to the presence of major key players, high disposable income, rise in the prevalence of pre-diabetes, high healthcare expenditure and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing research and development activities, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Abnormal glucose tolerance treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Abnormal Glucose Tolerance Treatment Market Share Analysis
Abnormal glucose tolerance treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to abnormal glucose tolerance treatment market research.
The major players covered in the abnormal glucose tolerance treatment market report are Bristol-Myers Squibb Company, Sanofi, Teva Pharmaceutical Industries Ltd., SHIONOGI & Co., Ltd., Amneal Pharmaceuticals LLC., Apotex Inc., Accel Pharma Inc, Nostrum Pharmaceuticals LLC., GlaxoSmithKline plc, Mylan N.V., Auro Pharma Inc, Cardinal Health, Takeda Pharmaceutical Company Limited, MedPharm Ltd., Sun Pharmaceutical Industries Ltd., Shouguang Fukang Pharmaceutical Co., Ltd., Shandong Keyuan Pharmaceutical Co, Ltd., Merck KGaA, Bayer AG, CKD BiO Corp., and Livzon, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-